The abstract is read at the publisher; the summary is JClub's.
Human pluripotent stem cell–derived kidney organoids can be generated reproducibly and engraft after infusion into ex vivo porcine kidneys during normothermic machine perfusion.
- Why it matters: Scalable production methods are needed to generate large numbers of kidney organoids while preserving differentiation fidelity for therapeutic use.
- What they did: The authors used a scalable hPSC-kidney organoid derivation protocol, validated differentiation with single-cell RNA sequencing, imaging, metabolic assays, and CRISPR-Cas9 fluorescent reporters, then infused organoids into ex vivo porcine kidneys on normothermic machine perfusion.
- The result: After perfusion and in vivo transplantation, human-origin cells were detected and immune responses were evaluated, supporting feasibility and viability for ex vivo cell-based therapies in clinical trials.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.